Structural and functional studies on the interaction of adenovirus fiber knobs and desmoglein 2

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11346-11362

  Wang, Hongjie ^a   Yumul, Roma ^a   Cao, Hua ^a   Ran, Liang ^c   Fan, Xiaolong ^c   Richter, Maximilian ^a   Epstein, Forrest ^a   Gralow, Julie ^d   Zubieta, Chloe ^e   Fender, Pascal ^f   Liebera, André ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BEIJING NORMAL UNIVERSITY   (China)

^d USA   (United States)

^e EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

^f EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CETUXIMAB; DESMOGLEIN 2; DOXORUBICIN; FIBER KNOB PROTEIN; IRINOTECAN; JO 0 ANTIBODY; JO 1 ANTIBODY; JO 2 ANTIBODY; JO 4 ANTIBODY; PACLITAXEL; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENTIATION; EPITHELIUM CELL; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 3; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REPEATED DRUG DOSE; SEROTYPE; TRIPLE NEGATIVE BREAST CANCER; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY; VIRUS MUTATION;

ADENOVIRUSES, HUMAN; CAPSID PROTEINS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DESMOGLEIN 2; DNA MUTATIONAL ANALYSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RECEPTORS, VIRUS; RECOMBINANT PROTEINS;

EID: 84886899795     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01825-13     Document Type: Article

References (43)

1. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK, III, Urban N, Drescher C, Hemminki A, Fender P, Lieber A. 2011. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 17:96-104.
2. Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, Lieber A. 2011. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J. Virol. 85:6390-6402.
3. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, Song H, Bartek J, Fender P, Lieber A. 2011. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res. 71:7080-7090.
4. Wang H, Beyer I, Persson J, Song H, Li Z, Richter M, Cao H, van Rensburg R, Yao X, Hudkins K, Yumul R, Zhang XB, Yu M, Fender P, Hemminki A, Lieber A. 2012. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J. Virol. 86:6286-6302.
5. Beyer I, Cao H, Persson J, Song H, Richter M, Feng Q, Yumul R, van Rensburg R, Li Z, Berenson R, Carter D, Roffler S, Drescher C, Lieber A. 2012. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin. Cancer Res. 18: 3340-3351.
6. Wang H, Tuve S, Erdman DD, Lieber A. 2009. Receptor usage of a newly emergent adenovirus type 14. Virology 387:436-441.
7. Carr MJ, Kajon AE, Lu X, Dunford L, O'Reilly P, Holder P, De Gascun CF, Coughlan S, Connell J, Erdman DD, Hall WW. 2011. Deaths associated with human adenovirus-14p1 infections, Europe, 2009-2010.Emerg. Infect. Dis. 17:1402-1408.
8. Girouard G, Garceau R, Thibault L, Oussedik Y, Bastien N, Li Y. 2013. Adenovirus serotype 14 infection, New Brunswick, Canada, 2011. Emerg. Infect. Dis. 19:119-122.
9. Kajon AE, Lu X, Erdman DD, Louie J, Schnurr D, George KS, Koopmans MP, Allibhai T, Metzgar D. 2010. Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. J. Infect. Dis. 202:93-103.
10. Wang H, Liaw YC, Stone D, Kalyuzhniy O, Amiraslanov I, Tuve S, Verlinde CL, Shayakhmetov D, Stehle T, Roffler S, Lieber A. 2007. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol. 81:12785-12792.
11. Strauss R, Sova P, Liu Y, Li Z-Y, Tuve S, Pritchard D, Brinkkoetter P, Moller T, Wildner O, Pesonen S, Hemminki A, Urban N, Drescher C, Lieber A. 2009. Epithelial phenotype of ovarian cancer mediates resistance to oncolytic adenoviruses. Cancer Res. 15:5115-5125.
12. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A. 2007. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67:5929-5939.
13. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A. 2006. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80:12109-12120.
14. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. 2000. Efficient gene transfer into human CD34 cells by a retargeted adenovirus vector. J. Virol. 74:2567-2583.
15. Cadwell RC, Joyce GF. 1994. Mutagenic PCR. PCR Methods Appl. 3:S136-S140.
16. Cadwell RC, Joyce GF. 1992. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2:28-33.
17. Incardona MF, Bourenkov GP, Levik K, Pieritz RA, Popov AN, Svensson O. 2009. EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis. J. Synchrotron Radiat. 16:872-879.
18. Kabsch W. 2010. Integration, scaling, space-group assignment and postrefinement. Acta Crystallogr. D Biol. Crystallogr. 66:133-144.
19. Kabsch W. 2010. Xds. Acta Crystallogr. D Biol. Crystallogr. 66:125-132.
20. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40: 658-674.
21. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
22. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
23. Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J, Welsh MJ. 2002. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110:789-799.
24. Durmort C, Stehlin C, Schoehn G, Mitraki A, Drouet E, Cusack S, Burmeister WP. 2001. Structure of the fiber head of Ad3, a non-CARbinding serotype of adenovirus. Virology 285:302-312.
25. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A. 2011. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6:e16186. doi: 10.1371/journal.pone.0016186.
26. Ueno NT, Zhang D. 2011. Targeting EGFR in triple negative breast cancer. J. Cancer 2:324-328.
27. Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM. 1999. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286:1579-1583.
28. Persson BD, Reiter DM, Marttila M, Mei YF, Casasnovas JM, Arnberg N, Stehle T. 2007. Adenovirus type 11 binding alters the conformation of its receptor CD46. Nat. Struct. Mol. Biol. 14:164-166.
29. Pache L, Venkataraman S, Nemerow GR, Reddy VS. 2008. Conservation of fiber structure and CD46 usage by subgroup B2 adenoviruses. Virology 375:573-579.
30. Metzgar D, Osuna M, Kajon AE, Hawksworth AW, Irvine M, Russell KL. 2007. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J. Infect. Dis. 196:1465-1473.
31. Anonymous. 2007. Acute respiratory disease associated with adenovirus serotype 14-four states, 2006-2007. MMWR Morb. Mortal. Wkly. Rep. 56:1181-1184.
32. Lewis PF, Schmidt MA, Lu X, Erdman DD, Campbell M, Thomas A, Cieslak PR, Grenz LD, Tsaknardis L, Gleaves C, Kendall B, Gilbert D. 2009. A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. J. Infect. Dis. 199:1427-1434.
33. Esposito DH, Gardner TJ, Schneider E, Stockman LJ, Tate JE, Panozzo CA, Robbins CL, Jenkerson SA, Thomas L, Watson CM, Curns AT, Erdman DD, Lu X, Cromeans T, Westcott M, Humphries C, Ballantyne J, Fischer GE, McLaughlin JB, Armstrong G, Anderson LJ. 2010. Outbreak of pneumonia associated with emergent human adenovirus serotype 14-southeast Alaska, 2008. J. Infect. Dis. 202:214-222.
34. Tang L, An J, Xie Z, Dehghan S, Seto D, Xu W, Ji Y. 2013. Genome and bioinformatic analysis of a HAdV-B14p1 virus isolated from a baby with pneumonia in Beijing, China. PLoS One 8:e60345. doi:10.1371/journal.pone.0060345.
35. Trei JS, Johns NM, Garner JL, Noel LB, Ortman BV, Ensz KL, Johns MC, Bunning ML, Gaydos JC. 2010. Spread of adenovirus to geographically dispersed military installations, May-October 2007. Emerg. Infect. Dis. 16:769-775.
36. Cupelli K, Muller S, Persson BD, Jost M, Arnberg N, Stehle T. 2010. Structure of adenovirus type 21 knob in complex with CD46 reveals key differences in receptor contacts among species B adenoviruses. J. Virol. 84:3189-3200.
37. Cupelli K, Stehle T. 2011. Viral attachment strategies: the many faces of adenoviruses. Curr. Opin. Virol. 1:84-91.
38. Trinh HV, Lesage G, Chennamparampil V, Vollenweider B, Burckhardt CJ, Schauer S, Havenga M, Greber UF, Hemmi S. 2012. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J. Virol. 86:1623-1637.
39. Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, Lieber A, Pesonen S, Hemminki A. 2012. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol. Ther. 20:1821-1830.
40. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. 2007. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J. Virol. 81:13149-13157.
41. Campos SK, Parrott MB, Barry MA. 2004. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 9:942-954.
42. Zeng Y, Pinard M, Jaime J, Bourget L, Uyen Le P, O'Connor-McCourt MD, Gilbert R, Massie B. 2008. A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism. J. Gene Med. 10:355-367.
43. Strauss R, Lieber A. 2009. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr. Opin. Mol. Ther. 11:513-522.